Results 231 to 240 of about 8,133 (247)
Possible Mechanisms and Molecular Signaling of Incretins against the Development of Type 2 Diabetes Mellitus [PDF]
Current Molecular Pharmacology, 2023 The increasing number of cases of diabetes mellitus (DM) and related diseases has become a global health concern. In this context, controlling blood glucose levels is critical to prevent and/or slow down the development of diabetes-related complications.
Zatollah Asemi +2 more
exaly +2 more sources
Incretins or Anti-Incretins? A New Model for the “Entero-Pancreatic Axis” [PDF]
Hormone and Metabolic Research, 2015 The role of incretins in glucose homeostasis is well known. Yet, in recent years, the sustained weight loss and rapid glycemic control following bariatric surgery has challenged our understanding of the intestinal-pancreatic interaction. This in turn led
Geltrude Mingrone, F Rubino
exaly +2 more sources
Incretins and Lipid Metabolism [PDF]
Current Medicinal Chemistry, 2018 Background: Recent findings indicate that incretin hormones and incretin-based therapies may affect the metabolism of lipoproteins, although the corresponding mechanisms are not clearly defined.
Moses Elisaf, Vasilis Tsimihodimos
exaly +2 more sources
The physiology and pharmacology of incretins in type 2 diabetes mellitus [PDF]
Diabetes, Obesity and Metabolism, 2008 Udgivelsesdato: 2008/8Two incretin hormones, glucose-dependent insulinotropic polypeptide (GIP) and glucagon-like peptide (GLP)-1, help control blood glucose levels by affecting plasma insulin levels in response to oral glucose intake - this is known as ...
Jens Juul Holst
exaly +2 more sources
Modulation of Diabetes by Natural Products and Medicinal Plants via Incretins [PDF]
Planta Medica, 2019 Incretins are metabolic hormones released after a meal that increase insulin secretion from pancreatic β-cells. The two main incretins are the intestinal peptides glucagon-like peptide-1 and glucose-dependent insulinotropic polypeptide.
Flavio Francini +2 more
exaly +3 more sources
Incretins and SGLT-2i Therapy of Type 2 Diabetes – Real Life Study of Their Therapeutic and Economic Effects [PDF]
Frontiers in Pharmacology, 2019 AimIncretins [dipeptidyl peptidase-4 inhibitors (DPP-4i) and glucagon-like peptide 1 RA (GLP-1 RA)] and sodium-glucose cotransporter-2 inhibitors (SGLT-2i) groups are now routinely used for type 2 diabetes therapy and comprise a large number of medicinal
Guenka Petrova +2 more
exaly +3 more sources
Impaired beta cell sensitivity to incretins in type 2 diabetes is insufficiently compensated by higher incretin response [PDF]
Nutrition, Metabolism and Cardiovascular Diseases, 2017 Background and aims The incretin effect is impaired in type 2 diabetes (T2D), but the underlying mechanisms are only partially understood. We investigated the relationships between the time course of the incretin effect and that of glucose-dependent ...
Jens Juul Holst +2 more
exaly +2 more sources
Some of the next articles are maybe not open access.
Related searches:
Related searches:
Incretins in fibrocalculous pancreatic diabetes: A unique subtype of pancreatogenic diabetes
Journal of Diabetes, 2021Sujoy Ghosh +2 more
exaly